Shop in your local currency and language

Choose another country or region to see specific content for your location and shop online.

United Kingdom

Biologics process development. Built to hold.

From process design to manufacturing readiness, we help you make process decisions that don't cause rework or unnecessary variation.

Every experiment counts

Every process development program hits inflection points—moments that either compound your progress or stall it. Will your process carry through to scale, or will it force months of rework when time and margins are tight? And is the standard platform approach the best one for your molecule?

At Cytiva, we see those moments as opportunities to build momentum. We bring together the methods, tools, and expertise that help your team make stronger decisions earlier—so your process holds up at every stage, not just the one you're in now.

Let’s make every experiment count

Process resilience at bench, pilot, and GMP scale

A good process should be transferable, scalable, and defensible. We help you get there with proven technologies, deep application expertise, and practical workflow tools for upstream and downstream process development.

Process design, analytics, and troubleshooting

Model, screen, and optimize upstream and downstream unit operations—using DoE, HTPD, digital tools, or our scientists' hands-on support.

Proven consumables and hardware

The resins, membranes, and systems already used in most approved mAbs and gene therapies—designed for scale-up from day one.

Tech transfer and regulatory readiness

Prepare for site transfer and regulatory filing with complete documentation, data packages, and hands-on submission support.

Hands-on process development or in-house enablement

Our process development scientists work as an extension of your team or take the lead entirely—matched to your capacity, goals, and timeline.

From momentum to patient impact

In 2025, our technologies enabled advanced therapies for 400 million patients1 across 200+ diseases and conditions2 worldwide.

You can rely on us and our deep scientific expertise, equipment, and product engineers to help you make the same translatable difference, whether you're working with traditional mAbs, novel antibodies, viral vectors, or mRNA.

1An individual patient may be counted more than once if treated with multiple therapies. 
2Diseases and conditions according to WHO ICD classification.

From momentum to patient impact

Real-world results

Scientists at Boehringer Ingelheim, Molecular Partners, and Roche share tips for using ÄKTA avant™ chromatography systems for process development.

Real-world results

Solutions across modalities

Every modality has different process challenges. mAbs and antibody variants demand platform consistency at scale. mRNA and oligonucleotides require tight control over formulation, purification, and rapidly evolving manufacturing methods. Gene and cell therapies need scalable processes built around inherently variable biology. We support all of them with proven equipment, optimized workflows, and hands-on expertise.

Solutions across modalities

Process development services that meet you where you are

From rapid proof-of-concept studies to full upstream and downstream process development and design, optimization, and even tech transfer—we work with your scientists to get you to your next milestone.

Learn more about our process development services.

Process development services that meet you where you are

Ask us anything

Tell us about your molecule and timeline, and we'll recommend a starting point. Our process development specialists can help you choose a product, solve a problem, or order samples to try in your lab.

Ask us anything

Frequently asked questions about process development

Did you find what you were looking for?